Cabaletta Bio

1. Cabaletta Bio corporate financingmid-2026Cabaletta Bio corporate financing, mid-2026, routine
2. MG program corporate updateMid-2026MG program corporate update, Mid-2026, routine
3. MG registrational design corporate updatemid-2026MG registrational design corporate update, mid-2026, routine
4. RESET-MG FDA decisionmid-2026RESET-MG FDA decision, mid-2026, routine
5. Rese-cel (CABA-201) - RESET-SLE and2H 2026Rese-cel (CABA-201) - RESET-SLE and, 2H 2026, notable
6. PV / SLE Cellares manufacturing2H 2026PV / SLE Cellares manufacturing, 2H 2026, routine
7. SSc-ILD registrational study pivotal start4Q 2026SSc-ILD registrational study pivotal start, 4Q 2026, notable
8. Rese-cel (CABA-201) - Myositis BLA2027Rese-cel (CABA-201) - Myositis BLA, 2027, material
9. RESET-Myositis pivotal toplineMid-2027RESET-Myositis pivotal topline, Mid-2027, notable
10. Myositis BLA filingmid-2027Myositis BLA filing, mid-2027, routine
11. Myositis BLA JDM filing2H 2027Myositis BLA JDM filing, 2H 2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.